Work

Mammaglobin-A is a target for breast cancer vaccination

Year: 2016

Type: article

Abstract: We recently completed a phase 1 clinical trial demonstrating the safety of a mammaglobin-A DNA vaccine in patients with metastatic breast cancer. We are currently enrolling patients with early stage breast cancer in a phase 1b clinical trial. The mammaglobin-A DNA vaccine will be administered concurrently with neoadjuvant endocrine therapy, providing a unique opportunity to examine the impact of vaccination in the tumor microenvironment.

Source: OncoImmunology

DOI: 10.1080/2162402x.2015.1069940

Authors: Samuel W. Kim, Peter Goedegebuure, William E. Gillanders

Institutions: Washington University in St. Louis, Barnes-Jewish Hospital, Alvin J. Siteman Cancer Center

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913